GSK126

Target: This ligand targets enhancer of zeste homolog 2 (EZH2), the catalytic PRC2 methyltransferase subunit in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for enhancer of zeste homolog 2 (EZH2), the catalytic PRC2 methyltransferase subunit. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings enhancer of zeste homolog 2 (EZH2) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated BRD4 Degradation: GSK126 can be used as a ligand component in PROTAC designs to recruit an E3 ligase and drive ubiquitination-dependent degradation of BRD4. This enables mechanistic studies of BRD4 removal, including mapping degradation kinetics, determining proteasome dependence, and comparing effects versus BRD4 inhibition on transcriptional programs.

• E3 Ligase Recruitment Optimization: Incorporate GSK126 into PROTAC scaffolds to systematically vary linker length, attachment sites, and E3 ligase ligands. This supports optimization of ternary complex formation and degradation potency, allowing researchers to identify structural features that maximize target engagement, ubiquitination efficiency, and sustained BRD4 turnover.

• Target Engagement and Kinetics Studies: Use GSK126-based PROTACs to quantify how ligand affinity and PROTAC architecture influence BRD4 residence time and degradation rate. Time-course experiments with immunoblotting or proteomics can distinguish rapid degradation from transient engagement, clarifying how degradation correlates with downstream chromatin and gene-expression changes.

• Proteasome-Dependent Mechanism Validation: Employ GSK126-derived PROTAC constructs to confirm that BRD4 loss proceeds through the ubiquitin–proteasome pathway. Researchers can test dependence on proteasome inhibition, assess ubiquitinated intermediates, and evaluate whether degradation requires functional E3 ligase recruitment, thereby validating targeted protein degradation mechanisms.

GSK126 is a EZH2 methyltransferase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of GSK126 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.